GATM Genotype

Creatine is the molecule your brain and muscles use to recharge their energy supply between bursts of activity. The GATM (glycine amidinotransferase) gene builds the first enzyme in the two-step pathway that makes creatine inside your body, and rare inherited variants in this gene can shut that pathway down.

Knowing your GATM status matters because the most severe version of this condition is one of the few inherited metabolic disorders that responds well to treatment, especially when caught before symptoms appear. The result is a one-time, lifetime read on a piece of your inherited biology that standard chemistry panels do not capture.

What GATM Actually Does

The GATM gene encodes an enzyme called AGAT (arginine:glycine amidinotransferase), which performs the first of two chemical steps your body uses to make creatine. AGAT transfers a chemical group from the amino acid arginine onto the amino acid glycine, producing a compound called guanidinoacetate, along with ornithine as a byproduct. A second enzyme called GAMT (guanidinoacetate methyltransferase) then converts guanidinoacetate into creatine itself.

Creatine then feeds a recycling system inside your cells (the creatine kinase circuit) that buffers the energy supply for tissues with high demand, like brain, skeletal muscle, and heart. In animal studies, AGAT activity is influenced by thyroid hormone and growth hormone, though these regulatory relationships are not well established in human clinical contexts. The availability of arginine and citrulline also affects how the enzyme functions. AGAT is expressed in tissues including the placenta, where its activity changes across pregnancy.

AGAT Deficiency from GATM Variants

When both copies of the GATM gene carry damaging variants, the result is AGAT deficiency, an inherited disorder of creatine synthesis. Without working AGAT, your body cannot make its own creatine, and brain creatine levels fall well below normal. This is one of the cerebral creatine deficiency disorders, a small family of conditions that share the common thread of low brain creatine.

The clinical picture in AGAT deficiency includes developmental delay, intellectual disability, muscle weakness, and in some people, epilepsy. Seizures have long been recognized as part of the phenotype in roughly one in ten cases, and more recent reports suggest that epilepsy may be more common than previously appreciated. Because the underlying problem is too little creatine, the standard treatment is daily oral creatine supplementation, which can restore brain creatine and improve symptoms when started early enough. Patients treated in early infancy have gone on to normal cognitive development.

Kidney Function and Chronic Kidney Disease

GATM is not only a brain story. A separate set of variants in GATM can cause kidney disease. Single-copy (monoallelic) mutations in GATM have been linked to renal Fanconi syndrome and kidney failure in a study of affected family members across multiple lineages, with researchers proposing that abnormal AGAT protein accumulates in kidney cells and drives scarring of the kidney tissue.

Common population-level genetic variation in GATM also influences ongoing kidney function. A Mendelian randomization study found that higher GATM expression was associated with a lower risk of chronic kidney disease and with better filtration capacity, measured as estimated glomerular filtration rate. The same locus has surfaced in a genome-wide association study of kidney function in African populations.

One nuance worth knowing: because GATM helps produce creatine, and the breakdown of creatine generates the creatinine your kidneys clear, common GATM variants can shift serum creatinine levels by changing how much creatine your body makes rather than by changing actual kidney filtration. That means a creatinine-based estimate of kidney function can be misleading in some carriers. If you carry a GATM variant that affects kidney biology, monitoring kidney function over time becomes more important than the genetic result alone, and a panel that includes cystatin C, which does not depend on creatine metabolism, gives a more reliable read alongside creatinine.

Statin Response and Muscle Side Effects

GATM has been investigated as a possible explanation for why some people develop muscle pain on statins. The original report from Mangravite and colleagues found that one GATM variant (rs9806699) was associated with a lower risk of statin-related muscle problems, with myopathy defined by elevated creatine kinase plus muscle pain. A larger replication study in 715 dyslipidemic individuals did not confirm that association. A later meta-analysis pooling six studies found a modest protective association of this variant against mild statin-induced myopathy, but no significant signal for severe cases, so the picture is mixed rather than settled.

The practical takeaway: GATM is a candidate gene in the statin-muscle puzzle, but the evidence is not strong enough yet to use a GATM result alone to predict who will tolerate statins. If you carry a variant and have struggled with statin side effects, your GATM status is one piece of context to bring into the conversation, not a final answer.

Reconciling the Pattern

At first glance, GATM looks contradictory. Less function causes severe disease in childhood, more function looks protective for kidneys, and a single variant might either raise or lower a specific risk depending on which study you read. The framework that resolves this is that GATM is not a simple good-number-bad-number gene. It is an enzyme blueprint, and different variants disrupt different parts of how that enzyme is made, where it ends up in the cell, and how much creatine your body produces as a result. The clinical meaning of your result depends on which specific variant you carry, not on the gene as a whole.

One-Time Result, Lifelong Use

GATM is a fixed genetic test. Your genotype was set at conception and will not change, so this is a once-in-a-lifetime measurement. There is no trend line to track for the gene itself, and there is no need to repeat the test unless a confirmatory method is warranted because the original call was uncertain.

The value of the result comes from what you do with it for years afterward. If you carry a variant relevant to kidney biology, that is a reason to monitor kidney function regularly with a kidney function panel that includes creatinine, cystatin C, and estimated glomerular filtration rate. If you carry a variant linked to creatine biosynthesis, biochemical confirmation with plasma guanidinoacetate and creatine levels becomes the relevant follow-up. The cadence of those companion tests, not the genotype itself, is what you trend over time.

What to Do With an Unexpected Result

An unexpected GATM result is not an emergency, but it should trigger a structured workup rather than a wait-and-see approach. The first step is confirmation. SNP-based genotyping panels can occasionally produce ambiguous calls, and sequencing-based confirmation is appropriate before making downstream decisions on the strength of a single result.

If your variant has implications for creatine synthesis, the relevant follow-up is biochemical testing of plasma and urine guanidinoacetate and creatine, which can show whether your body is actually producing creatine normally. If your variant has implications for kidney function, the follow-up is more aggressive and more frequent kidney monitoring, with attention to both filtration markers and urinary protein. A referral to a genetic counselor is worth considering for any unexpected result, because the implications extend to siblings, children, and parents who share your DNA.

Penetrance and Family Implications

Carrying a GATM variant does not always mean you will develop disease. The chance that a variant actually causes the associated condition (a concept called penetrance) varies by variant. The specific heterozygous missense variants tied to dominant kidney disease have been described as fully penetrant in the families studied, while common population-level variants identified in genome-wide studies have small effect sizes and much less certain individual risk. Severe AGAT deficiency requires two damaged copies of the gene. Single-copy carriers are usually unaffected for the creatine-synthesis condition, though some single-copy variants have been tied to kidney disease in specific families. Your relatives share roughly half of your DNA on average, so a clinically relevant result is also relevant information for them.